What to bring to a visit for joint soreness

What to tell the doctor first

Point to the exact spot that hurts. Show which movement brings on the soreness.

Say if the joint swells, gives way, or wakes you. Don't leave out a fall, fever, weakness, or numbness.

What to do during the exam

The doctor checks strength, movement, swelling, and sore spots. You may walk or move the joint several ways.

An X-ray shows wear while the exam shows how you move. The X-ray is one photo, not the whole visit.

Speak up when a movement hurts or feels weak. Ask what the exam means for walking, sleep, and daily chores.

What to ask before you pay

Write down the full treatment name and total price. Ask who performs it and which later visits the price includes.

If material comes from your body, ask where staff take it. Then ask how they prepare it and what soreness to expect.

Federal registration means a clinic or product filed its name with the government. It doesn't prove that the care works for your joint.

What to do if it doesn't settle

When soreness continues, QC Kinetix may discuss regenerative treatments, procedures using material from your body. Staff prepare that material at the clinic.

The clinic calls its joint exam and care staff medical providers. You aren't required to decide during the first visit.

Call for prompt care if sudden heat or severe swelling appears. A clinic discussion can't take the place of urgent help.

Sources

1. The International Society for Cell & Gene Therapy position statement holds that the acronym MSC should mean mesenchymal STROMAL cells and should only be called stem cells where rigorous in vitro and in vivo evidence of stemness exists for that specific preparation.

   Viswanathan S, et al. — Mesenchymal stem versus stromal cells: International Society for Cell & Gene Therapy (ISCT®) Mesenchymal Stromal Cell committee position statement on nomenclature. Cytotherapy, 2019. DOI: 10.1016/j.jcyt.2019.08.002.

2. The 2018 AAOS/NIH consensus work group recommended that minimally manipulated mixed cell preparations be called CELL THERAPY rather than stem cell therapy, and that their untested and uncharacterised nature be clearly communicated to patients and the public, because stem cells have properties these preparations do not meet.

   Chu CR, et al. — Optimizing Clinical Use of Biologics in Orthopaedic Surgery: Consensus Recommendations From the 2018 AAOS/NIH U-13 Conference. J Am Acad Orthop Surg, 2019. DOI: 10.5435/JAAOS-D-18-00305.

3. 21 CFR 1271.10(a) sets the four criteria a human cell or tissue product must meet to be regulated SOLELY under section 361 of the Public Health Service Act: it must be minimally manipulated; intended for homologous use only, as reflected by labeling and advertising; not combined with another article beyond water, crystalloids or a preserving agent; and either have no systemic effect and not depend on the metabolic activity of living cells, or else be for autologous use, use in a close blood relative, or reproductive use.

   US Code of Federal Regulations, Title 21 — 21 CFR 1271.10 - Are my HCT/P's regulated solely under section 361 of the PHS Act. , 2004.

4. FDA states in its consumer alert that the only FDA-approved stem cell products in the United States are blood-forming stem cells derived from umbilical cord blood, approved for disorders of the blood-forming system, and that NONE of these products - stem cells, stromal vascular fraction, umbilical cord blood, Wharton's jelly or amniotic fluid - has been approved for the treatment of any orthopedic condition, including osteoarthritis, tendonitis, disc disease, tennis elbow, back pain, hip pain, knee pain, neck pain or shoulder pain.

   US Food and Drug Administration, Center for Biologics Evaluation and Research — Consumer Alert on Regenerative Medicine Products Including Stem Cells and Exosomes. , 2020.

5. A 2025 randomized trial of 66 knee osteoarthritis patients compared a single adipose stromal vascular fraction injection, conventional rehabilitation alone, and the two combined over 12 months - a design that treats exercise-based rehabilitation as a genuine comparator rather than an afterthought.

   Lu J, et al. — Intraarticular injection of the stromal vascular fraction for the treatment of knee osteoarthritis a prospective randomized controlled clinical trial. Sci Rep, 2025. DOI: 10.1038/s41598-025-09398-w.

6. In a 480-patient, four-arm, multicenter randomized phase 2/3 trial, none of three orthobiologic cell injections - autologous bone marrow aspirate concentrate, autologous adipose stromal vascular fraction, or allogeneic umbilical cord tissue-derived mesenchymal stromal cells - was superior to any other, or to a corticosteroid injection control, on pain at 12 months.

   Mautner K, et al. — Cell-based versus corticosteroid injections for knee pain in osteoarthritis: a randomized phase 3 trial. Nat Med, 2023. DOI: 10.1038/s41591-023-02632-w.